UK bioscience companies form Rare Disease Industry Group
The BIA is committed ensuring patient access to treatments for rare and very rare conditions, sometimes referred to as orphan and ultra-orphan medicines...
List view / Grid view
News
Future has “never been brighter” for US biopharmaceuticals
PhRMA report highlights the healthy nature of the US biopharmaceuticals industry, which invests about $75bn annually in research and development and supports nearly 4.7m jobs across the country
Low-cost drugs package saves lives of people starting HIV treatment late
Treating people who start HIV treatment late with a package of low-cost drugs to prevent serious infections saves three lives for ...
NICE publishes new Parkinson’s clinical guidance
Parkinson’s disease is one of the most common neurological conditions, affecting an estimated 130,000 people in the UK, with an annual incidence of around 15-20 per 100,000. It mainly affects people aged 50 or over.
FDA clears first neonatal magnetic resonance imaging device
Today, the U.S. Food and Drug Administration cleared the first magnetic resonance imaging (MRI) device specifically for neonatal brain and head imaging in neonatal intensive care units (NICU)...
ISPE updates guidance on risk-based manufacturing
New ISPE guidance provides a scientific, risk-based approach for managing cross-contamination risk within shared facilities ...
Robots and carbon targets may signal the end of globalisation
Automation and 3D printing to environmental regulations are now spelling the beginning of the end for globalised manufacturing...
Codes of ethics cause problems for overseas operations
Corporate codes of ethics can have reverse effects and mask anomalies or social evils in operations outsourced to low-wage countries...
NICE recommends Cinqaero (reslizumab) for treatment of severe asthma
The National Institute for Health and Care Excellence (NICE) in England has recommended Teva Pharmaceutical Industries Ltd’s Cinqaero (reslizumab) in its Final Appraisal Determination (FAD).
Arvato Systems signs deal with SecurMed UK to deliver medicines verification
SecurMed UK, the UK Medicines Verification Organisation, is entering into a Letter of Intent with Arvato Systems as its IT blueprint service provider.
27 Phase III and 8 Phase II Alzheimer’s drugs on track to launch in next 5 years
Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years...
Oramed appoints Dr Simon Bruce as Vice President of Medical Affairs
Oramed announced today the appointment of Dr Simon Bruce MD to the newly created position of Vice President of Medical Affairs...
UK trails behind EU in cancer diagnosis & treatment
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
Cyber attacks top digital risk for life science companies
Digital risk calculator highlights cyber attacks and highly sensitive or valuable data as major risks for life sciences businesses
Breathable, wearable electronics on skin for long-term health monitoring
A hypoallergenic electronic sensor can be worn on the skin continuously for a week without discomfort, and is so light and thin that users forget they even have it on, says a Japanese group of scientists.
